Clinical Trial

The Epidemiology of Patients Treated With ATZ+BEV in Real Life Setting

Study acronym: MANIFEST-HCC
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 17, 2025 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.
Summary
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause of cancer-related death globally. This retrospective, multicentric study will be coordinated by Dr. Adrian Radu Vidra (Lead Investigator) from Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor" Cluj-Napoca (Coordinating Site) to further investigate the clinical and demographic profile of patients receiving first-line treatment with atezolizumab and bevacizumab in the real-world setting of clinical practice from Romania. Participants already taking the combination therapy as part of their regular medical care for HCC will be followed during 3 years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-28.
Trial Details
NCT Number NCT06903663
Lead Sponsor Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Collaborators: MDX Research
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 100 participants
Start Date 2025-04
Primary Completion 2025-07 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-17